The onset of immunological reaction against @entity14 is based on superficial changes in the malignant cell components following the formation of antigen structures. This explains the interest in the issue and defines the aim of the study. Over a 5-year period, in the Emergency Surgery Clinic, 86 @entity1 with histologically diagnosed @entity14 (46 @entity1 and 40 @entity1 ) are examined prior to surgery, and 107 @entity1 (55 @entity1 and 52 @entity1 )--after the operation. The @entity5 markers @entity787 , CA 19-9, @entity160 and immunoglobulin IgA are tested using ELISA and RIA methods. Conventional ultrasound, scintigraphic and CT studies are carried out to detect liver @entity3 . The obtained results undergo statistical processing with correlation analysis and sensitivity and specificity coefficients. Among those examined preoperatively elevated @entity787 levels ( @entity787 > 2.5 ng/ml) are recorded in 42 cases (48.9%), and for CA 19-9 (CA 19-9 > 37 E/ml)--in 40 (46.5%). From the @entity1 with complicated @entity14 in the postoperative period 83 are clinically healthy (77.6%); of the latter marker-positive are 16 (19.3%), and marker-negative--67 (80.7%). Relapses and @entity3 are registered in 24 cases (22.4%) of which marker-positive--19 (79.2%). Liver and abdominal lymph node @entity3 are detected by US, scintigraphy and CT study. All three imaging methods contribute to diagnose liver @entity3 in 14 @entity1 (13%). In 32 @entity1 (18 @entity1 and 14 @entity1 ) postsurgical monitoring of immunological IgA levels and @entity5 markers is done over period ranging from 7-10 days to 2 years postoperatively. Correlative dependences between IgA and @entity787 (R = +0.99), and between IgA and CA 19-9 (R = +0.97) are also documented. The sensitivity of both markers ( @entity787 and CA 19-9) is low, varying between 38 and 51 per cent, with specificity amounting to 61-67 per cent. The paradoxically high elevation of @entity5 markers prior to operation shows a constant decrease at 3 months after surgery. CONCLUSIONS: 1. The sensitivity of both markers ( @entity787 and CA 19-9) is low (38-51%), and that is why their use in screening examinations lacks clinical relevance. 2. @entity787 specificity is by no means high (61-67%), and it may become positive in a number of @entity66 ( @entity1575 and @entity99 , @entity32 diseases of GIT and lungs). 3. Plasma @entity787 and CA 19-9 levels correlate well with the neoplastic process progression/regression. 4. Preoperative @entity787 level has a prognostic value for postsurgical relapses. 5. High IgA levels are indicators for relapses or @entity3 from @entity14 . 6. Tumor histological verification correlates also with the high @entity787 levels and with the depth of @entity5 infiltration into the intestinal wall. 7. The dynamic assessment of @entity5 markers postoperatively has a high informative value in all @entity14 @entity1 . 8. Pre- and postoperative high @entity787 levels are observed in @entity1 assigned to the poor prognosis group, and should be given adjuvant therapy.

[The pre- and postoperative monitoring of the immunological indices and XXXX markers in @entity14 ].

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity66 :: ('MESH:D004194', 'Disease') :: ['nononcological diseases'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity787 :: ('1084', 'Gene') :: ['CEA'] @entity160 :: ('174', 'Gene') :: ['AFP'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal carcinoma'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity1575 :: ('MESH:D008103', 'Disease') :: ['liver cirrhosis'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatitis']
@entity5 :: (MESH:D009369,Disease) :: ['tumor']
